All In Biotech

Free tool

FAERS Monitor: Renflexis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761054 or its brand name (Renflexis, Infliximab-Abda). Reports on generic versions are filed under their own applications.

Reports

61,715

Serious

59,686

97% of reports

Hospitalization

21,938

Death reported

7,134

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use21,242
  • condition aggravated13,192
  • drug ineffective12,511
  • intentional product use issue10,146
  • arthralgia8,428
  • fatigue6,811
  • pain6,480
  • inappropriate schedule of product administration5,922
  • nausea5,656
  • weight increased5,605
  • headache5,467
  • malaise5,372
  • diarrhoea5,324
  • rheumatoid arthritis5,190
  • rash4,947

Reports by year received

View as table
YearReports
2004271
2005759
2006337
2007524
2008480
2009722
2010478
2011404
2012786
2013258
2014260
2015387
2016570
2017882
20181,692
20193,614
20205,586
20214,852
20228,535
20238,837
20247,418
20258,932
20265,119

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,992,444 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intentional product use issueSignal10,14644.543.7383,122
rheumatoid arthritisSignal5,19016.315.871,392
condition aggravatedSignal13,19215.415.2172,565
inappropriate schedule of product administrationSignal5,92211.511.355,632
weight increasedSignal5,6058.78.537,762
off label useSignal21,2428.48.4142,010
arthralgiaSignal8,4287.06.943,567
malaiseSignal5,3724.24.113,280
rashSignal4,9473.93.810,770
painSignal6,4803.63.512,538
drug ineffectiveSignal12,5113.33.220,671
fatigueSignal6,8113.02.99,339
headacheSignal5,4673.02.97,392
diarrhoeaSignal5,3242.82.86,425
nauseaSignal5,6562.42.44,986

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.